Skip to main content

Tafinlar Receives Breakthrough Therapy Designation for Lung Cancer

February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology - FDA Approvals

A few days after the approval of the combination of the 2 melanoma drugs, the FDA approved dabrafenib (Tafinlar) as a breakthrough therapy designation for lung cancer based on interim results from an ongoing phase 2 clinical trial. (January 13, 2014)

Related Items
Chikungunya Vaccine Fetches FDA Nod for Persons Aged ≥12 Years
Online First published on March 19, 2025 in Infectious Diseases, FDA Approvals
FDA OKs Subcutaneous Apomorphine Infusion for Parkinson’s Treatment
Online First published on March 14, 2025 in FDA Approvals, Mental Health
FDA Approves First-in-Class Option for Acute Pain
Online First published on February 26, 2025 in FDA Approvals, Pain
AXS-07 Gets Nod for Acute Migraine Treatment
Online First published on February 26, 2025 in FDA Approvals, Neurology
FDA OKs Rapid-Acting Insulin Biosimilar Product
Online First published on February 19, 2025 in Biosimilars, Cardiometabolic Health, FDA Approvals
Last modified: August 30, 2021